ProFound AI Software V3.0
K203822iCAD Inc. · cleared 2021-03-12 · product code QDQ · Radiology
Premarket evidence — what FDA accepted
source quote (p.3)
“ProFound AI® V3.0 is a computer-assisted detection and diagnosis (CAD) software device intended to be used concurrently by interpreting physicians while reading digital breast tomosynthesis (DBT) exams from compatible DBT systems.”
source quote (p.5)
“The ProFound AI algorithm uses deep learning technology to process feature computations and uses pattern recognition to identify suspicious breast lesions appearing as soft tissue densities or clusters of calcifications.”
Validation studies (2)
Retrospective clinical
sample size not stated
endpoints: case sensitivity; FP rate per 3D volume; Area Under the localized Receiver Operating Characteristic (ROC) Curve (AUC)
Retrospective clinical
sample size not stated
endpoints: case sensitivity; FP rate per 3D volume; AUC
Reported performance (0 observations)
FDA source did not state a quantitative performance metric — non-reporting is itself the signal.
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
- re_clearance
The FDA AI/ML device list shows a newer 510(k) K240417 (decision 2024-11-08) from iCAD, Inc. for a matching device line ("ProFound Detection (V4.0)") — a new clearance for the same line is a change event.
first seen 2026-07-08 · k_number:K240417
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).